DPP-4 inhibitors and their potential role in the manage

International Journal of Clinical Practice
60, 1454-1470
DOI: 10.1111/j.1742-1241.2006.01178.x

Citation Report

#	Article	IF	Citations
1	A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies. Current Medical Research and Opinion, 2007, 23, 1493-1507.	0.9	55
2	Homo obesus: A Metabotrophin-Deficient Species. Pharmacology and Nutrition Insight. Current Pharmaceutical Design, 2007, 13, 2176-2179.	0.9	59
3	Dipeptidyl Peptidase-4 Inhibitors: Clinical data and clinical implications. Diabetes Care, 2007, 30, 1344-1350.	4.3	181
4	Inhibition of Renal Dipeptidyl Peptidase IV Enhances Peptide YY1â€“36-Induced Potentiation of Angiotensin II-Mediated Renal Vasoconstriction in Spontaneously Hypertensive Rats. Journal of Pharmacology and Experimental Therapeutics, 2007, 323, 431-437.	1.3	19
5	Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus. Current Opinion in Endocrinology, Diabetes and Obesity, 2007, 14, 98-107.	1.2	62
6	DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with Î²-cell-specific overexpression of human islet amyloid polypeptide. Regulatory Peptides, 2007, 143, 97-103.	1.9	38
7	Pharmacokinetic and Pharmacodynamic Assessments of the Dipeptidyl Peptidase-4 Inhibitor PHX1149: Double-Blind, Placebo-Controlled, Single- and Multiple-Dose Studies in Healthy Subjects. Clinical Therapeutics, 2007, 29, 1692-1705.	1.1	28
8	Sitagliptin phosphate: A DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Clinical Therapeutics, 2007, 29, 2614-2634.	1.1	82
9	DPP-4 inhibitors. Best Practice and Research in Clinical Endocrinology and Metabolism, 2007, 21, 517-533.	2.2	162
10	Individualising Therapy for Older Adults with Diabetes Mellitus. Drugs and Aging, 2007, 24, 851-863.	1.3	29
11	Gliptins: a new class of oral hypoglycaemic agent. QJM - Monthly Journal of the Association of Physicians, 2007, 100, 671-677.	0.2	23
12	Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for Type 2 diabetes. Expert Opinion on Investigational Drugs, 2007, 16, 533-545.	1.9	46
13	Oral antidiabetic agents in type 2 diabetes. Current Medical Research and Opinion, 2007, 23, 945-952.	0.9	91
14	Dipeptidyl peptidase IV (DDP IV) in NASH patients. Annals of Hepatology, 2007, 6, 242-250.	0.6	115
15	Modeling assisted rational design of novel, potent, and selective pyrrolopyrimidine DPP-4 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 3877-3879.	1.0	34
16	Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors. International Journal of Clinical Practice, 2007, 61, 29-37.	0.8	30
17	Potential role of oral DPP-4 inhibitors in the ADA/EASD consensus statement algorithm for achieving and maintaining tight glycaemic control in type 2 diabetes: recommendations for oral antidiabetic agents. International Journal of Clinical Practice, 2007, 61, 12-18.	0.8	2
18	Antidiabetic medications in overweight/obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin-based treatment on body weight. International Journal of Clinical Practice, 2007, 61, 19-28.	0.8	33

#	Article	IF	Citations
19	The Pathophysiology of Cardiovascular Disease in Diabetes Mellitus and the Future of Therapy. Journal of the Cardiometabolic Syndrome, 2007, 2, 108-113.	1.7	25
20	8-(3-(R)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a Highly Potent, Selective, Long-Acting, and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 Diabetes. Journal of Medicinal Chemistry, 2007, 50, 6450-6453.	2.9	254
22	DPP4 Inhibitors: a new approach in diabetes treatment. Advances in Therapy, 2008, 25, 627-643.	1.3	72
23	A three-dimensional pharmacophore model for dipeptidyl peptidase IV inhibitors. European Journal of Medicinal Chemistry, 2008, 43, 1603-1611.	2.6	20
24	Vildagliptin: clinical trials programme in monotherapy and combination therapy for type 2 diabetes. International Journal of Clinical Practice, 2008, 62, 15-23.	0.8	16
25	Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes*. Diabetes, Obesity and Metabolism, 2008, 10, 959-969.	2.2	205
26	The dipeptidyl peptidase-4 inhibitor PHX1149 improves blood glucose control in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 2008, 10, 293-300.	2.2	29
27	Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. The Cochrane Library, 2010, 2010, CD006739.	1.5	175
28	New Drugs for Type 2 Diabetes Mellitus. Drugs, 2008, 68, 2131-2162.	4.9	105
29	Dipeptidyl Peptidase-4 as a New Target of Action for Type 2 Diabetes Mellitus: A Systematic Review. Cardiology Clinics, 2008, 26, 639-648.	0.9	34
30	Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK. Current Medical Research and Opinion, 2008, 24, 385-399.	0.9	31
31	EnzymaticC-Demethylation of 1-[2-(5-tert-Butyl-[1,3,4]) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 307 Td (oxadiazole (LC15-0133) in Rat Liver Microsomes. Drug Metabolism and Disposition, 2008, 36, 485-489.	1.7	13
32	Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes. Expert Opinion on Investigational Drugs, 2008, 17, 845-853.	1.9	53
33	Effect of Sitagliptin, a Dipeptidyl Peptidaseâ€4 Inhibitor, on Blood Pressure in Nondiabetic Patients With Mild to Moderate Hypertension. Journal of Clinical Pharmacology, 2008, 48, 592-598.	1.0	184
34	Management of type 2 diabetes in the obese patient: current concerns and emerging therapies. Current Medical Research and Opinion, 2008, 24, 401-417.	0.9	13
35	Managing Type 2 Diabetes: Going Beyond Glycemic Control. Journal of Managed Care Pharmacy, 2008, 14, 1-22.	2.2	36
36	Pharmacological Management of Glycemic Control in the Geriatric Patient with Type 2 Diabetes Mellitus. The Consultant Pharmacist, 2009, 24, 45-63.	0.4	7
37	What are the practical implications for treating diabetes in light of recent evidence? Updated recommendations from the Global Partnership for Effective Diabetes Management. Diabetes and Vascular Disease Research, 2009, 6, 283-287.	0.9	17

#	Article	IF	Citations
38	Treatment Considerations for Diabetes: A Pharmacistâ€™s Guide to Improving Care in the Elderly. Journal of Pharmacy Practice, 2009, 22, 575-587.	0.5	1
39	DPP-4 Inhibitors in Clinical Practice. Postgraduate Medicine, 2009, 121, 70-100.	0.9	34
40	Pharmacokinetics of the Dipeptidyl Peptidase 4 Inhibitor Saxagliptin in Rats, Dogs, and Monkeys and Clinical Projections. Drug Metabolism and Disposition, 2009, 37, 1164-1171.	1.7	89
41	Saxagliptin Added to a Thiazolidinedione Improves Glycemic Control in Patients with Type 2 Diabetes and Inadequate Control on Thiazolidinedione Alone. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4810-4819.	1.8	201
42	Novel therapeutics for type 2 diabetes: Incretin hormone mimetics (glucagon-like peptide-1 receptor) Tj ETQq0 0 0 rgBT /Overlock 10 Tf		169
43	The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice. European Journal of Pharmacology, 2009, 602, 448-454.	1.7	33
44	Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Advances in Therapy, 2009, 26, 249-262.	1.3	81
45	Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. International Journal of Clinical Practice, 2009, 63, 46-55.	0.8	187
46	Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. International Journal of Clinical Practice, 2009, 63, 1395-1406.	0.8	229
47	Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA_{1c} without causing weight gain or increased hypoglycaemia. Diabetes, Obesity and Metabolism, 2009, 11, 1145-1152.	2.2	171
48	Alogliptin Use in Elderly People: A Pooled Analysis from Phase 2 and 3 Studies. Journal of the American Geriatrics Society, 2009, 57, 2011-2019.	1.3	71
49	Pharmacologic management of the older patient with type 2 diabetes mellitus. American Journal of Geriatric Pharmacotherapy, 2009, 7, 324-342.	3.0	64
50	DPP-4 inhibitors. Insulin, 2009, 4, 15-31.	0.2	6
51	Inhibition of dipeptidyl peptidase 4 by BI-1356, a new drug for the treatment of beta-cell failure in type 2 diabetes. Expert Opinion on Investigational Drugs, 2009, 18, 835-838.	1.9	5
52	Probing multivalency for the inhibition of an enzyme: glycogen phosphorylase as a case study. New Journal of Chemistry, 2009, 33, 148-156.	1.4	29
53	Dipeptidyl peptidase IV(DPP IV): a novel emerging target for the treatment of type 2 diabetes. Journal of Nanjing Medical University, 2009, 23, 228-235.	0.1	10
54	Constitutive increase in active GLP-1 levels by the DPP4 inhibitor ASP4000 on a new meal tolerance test in Zucker fatty rats. Pharmacological Research, 2009, 60, 264-269.	3.1	2
55	Insulin, other hypoglycemic drugs, and glucagon. Side Effects of Drugs Annual, 2009, , 689-702.	0.6	1

#	Article	IF	Citations
56	Insulin, other hypoglycemic drugs, and glucagon. Side Effects of Drugs Annual, 2010, 32, 769-788.	0.6	0
57	Diabetes mellitus: new challenges and innovative therapies. EPMA Journal, 2010, 1, 138-163.	3.3	48
58	Glycaemic control in type 2 diabetes: Targets and new therapies. , 2010, 125, 328-361.		155
59	Synthesis of dipeptidyl peptidase-4 inhibitors: a brief overview. Tetrahedron, 2010, 66, 4919-4938.	1.0	47
60	Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. International Journal of Clinical Practice, 2010, 64, 1619-1631.	0.8	146
61	Reduced airway inflammation in CD26/DPP4â€deficient F344 rats is associated with altered recruitment patterns of regulatory T cells and expression of pulmonary surfactant proteins. Clinical and Experimental Allergy, 2010, 40, 1794-1808.	1.4	27
62	Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus. Core Evidence, 2010, 5, 23.	4.7	22
63	A Review of Exenatide in the Treatment of Type 2 Diabetes Mellitus. Clinical Medicine Insights Therapeutics, 2010, 2, CMT.S3489.	0.4	0
64	Type 2 Diabetes Comorbidities and Treatment Challenges: Rationale for DPP-4 Inhibitors. Postgraduate Medicine, 2010, 122, 71-80.	0.9	47
65	Saxagliptin: A dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus. American Journal of Health-System Pharmacy, 2010, 67, 1515-1525.	0.5	28
66	In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II Inhibitor, in Animals and Humans. Drug Metabolism and Disposition, 2010, 38, 405-414.	1.7	149
67	Dipeptidyl Peptidase IV Inhibition Alters the Hemodynamic Response to Angiotensin-Converting Enzyme Inhibition in Humans With the Metabolic Syndrome. Hypertension, 2010, 56, 581-583.	1.3	23
68	Saxagliptin for type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2010, 3, 325.	1.1	4
69	Identification and characterization of dipeptidyl peptidase IV enzyme activity in the American crocodile (Crocodylus acutus). Veterinary Immunology and Immunopathology, 2010, 136, 28-33.	0.5	4
70	Pharmacokinetics and metabolism of the dipeptidyl peptidase IV inhibitor carmegliptin in rats, dogs, and monkeys. Xenobiotica, 2010, 40, 840-852.	0.5	6
71	Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Clinical Science, 2010, 118, 31-41.	1.8	175
72	Management of Global Cardiovascular Risk in Older Subjects with Diabetes Mellitus. High Blood Pressure and Cardiovascular Prevention, 2010, 17, 53-58.	1.0	0
73	Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation). Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 1561-1576.	1.5	29

#	Article	IF	Citations
74	Effect of Sitagliptin as Add-on Therapy in Elderly Type 2 Diabetes Patients With Inadequate Glycemic Control in Taiwan. International Journal of Gerontology, 2011, 5, 103-106.	0.7	21
76	Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: A randomized controlled trial. Diabetes Research and Clinical Practice, 2011, 94, 217-224.	1.1	87
77	Management of diabetes mellitus in the elderly. Current Opinion in Endocrinology, Diabetes and Obesity, 2011, 18, 148-152.	1.2	32
78	The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis. Endocrine Journal, 2011, 58, 979-987.	0.7	69
79	Incretinâ€based therapies â€“ review of the physiology, pharmacology and emerging clinical experience. Internal Medicine Journal, 2011, 41, 299-307.	0.5	57
80	Pre-treatment with a DPP-4 Inhibitor is Infarct Sparing in Hearts from Obese, Pre-diabetic Rats. Cardiovascular Drugs and Therapy, 2011, 25, 13-20.	1.3	86
81	Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy. Advances in Therapy, 2011, 28, 447-459.	1.3	35
82	Aza-annulation on the 16-dehydropregnenolone, via tandem intermolecular Aldol process and intramolecular Michael addition. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 2232-2237.	1.0	16
83	Efficacy and Safety of Saxagliptin Combination Therapy in US Patients with Type 2 Diabetes. Postgraduate Medicine, 2011, 123, 63-70.	0.9	15
84	Isolation of dipeptidyl peptidase IV (DP 4) isoforms from porcine kidney by preparative isoelectric focusing to improve crystallization. Biological Chemistry, 2011, 392, 665-77.	1.2	5
85	Dipeptidyl Peptidase IV Regulates Proliferation of Preglomerular Vascular Smooth Muscle and Mesangial Cells. Hypertension, 2012, 60, 757-764.	1.3	31
86	Cardioprotective effects of incretin during ischaemia-reperfusion. Diabetes and Vascular Disease Research, 2012, 9, 256-269.	0.9	28
87	Determination of Sitagliptin with Fluorescamine in Tablets and Spiked Serum Samples by Spectrofluorimetry and a Degradation Study. Current Pharmaceutical Analysis, 2012, 8, 278-285.	0.3	13
88	Beneficial Effects of PKF275-055, a Novel, Selective, Orally Bioavailable, Long-Acting Dipeptidyl Peptidase IV Inhibitor in Streptozotocin-Induced Diabetic Peripheral Neuropathy. Journal of Pharmacology and Experimental Therapeutics, 2012, 340, 64-72.	1.3	41
89	Pharmacology, Efficacy, and Safety of Linagliptin for the Treatment of Type 2 Diabetes Mellitus. Annals of Pharmacotherapy, 2012, 46, 358-367.	0.9	11
90	ActualitÃ©s biologiques sur les angioedÃ¨mes Ã kinines. Revue Francophone Des Laboratoires, 2012, 2012, 39-52.	0.0	0
91	Synthesis and evaluation of [18F]exendin (9â€“39) as a potential biomarker to measure pancreatic Î²-cell mass. Nuclear Medicine and Biology, 2012, 39, 167-176.	0.3	49
92	Pharmacokinetic Study of Saxagliptin in Healthy Chinese Subjects. Clinical Drug Investigation, 2012, 32, 465-473.	1.1	11

#	Article	IF	Citations
93	Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Current Medical Research and Opinion, 2012, 28, 513-523.	0.9	153
94	Type 2 Diabetes Mellitus: A Review of Current Trends. Oman Medical Journal, 2012, 27, 269-273.	0.3	820
95	Clinical Implications of Cardiovascular Preventing Pleiotropic Effects of Dipeptidyl Peptidase-4 Inhibitors. American Journal of Cardiology, 2012, 109, 1681-1685.	0.7	60
96	Review of Linagliptin for the Treatment of Type 2 Diabetes Mellitus. Clinical Therapeutics, 2012, 34, 993-1005.	1.1	32
97	Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2â€ƒyears exposure in 24-week phase III trials followed by a 78-week open-label extension. International Journal of Clinical Practice, 2012, 66, 731-740.	0.8	36
98	New leads for DPP IV inhibition: structure-based pharmacophore mapping and virtual screening study. Archives of Pharmacal Research, 2013, 36, 1326-1337.	2.7	8
99	Protective effects of sitagliptin on myocardial injury and cardiac function in an ischemia/reperfusion rat model. European Journal of Pharmacology, 2013, 718, 105-113.	1.7	53
100	Enzyme responsive materials: design strategies and future developments. Biomaterials Science, 2013, 1, 11-39.	2.6	257
101	The importance of synthetic drugs for type 2 diabetes drug discovery. Expert Opinion on Drug Discovery, 2013, 8, 1339-1363.	2.5	37
102	Dipeptidyl peptidase-4 inhibitors: their role in the management of type 2 diabetes. South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care, 2013, 55, 508-510.	0.2	5
103	Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemiaâ€“reperfusion injury. International Journal of Cardiology, 2013, 167, 451-457.	0.8	83
104	DPP8 and DPP9 expression in cynomolgus monkey and Sprague Dawley rat tissues. Regulatory Peptides, 2013, 186, 26-35.	1.9	17
105	The Lipophilic Bullet Hits the Targets: Medicinal Chemistry of Adamantane Derivatives. Chemical Reviews, 2013, 113, 3516-3604.	23.0	517
106	The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis. Expert Opinion on Pharmacotherapy, 2013, 14, 259-267.	0.9	36
107	Prognostic implications of DPP-4 inhibitor vs. sulfonylurea use on top of metformin in a real world setting - results of the 1Âyear follow-up of the prospective DiaRegis registry. International Journal of Clinical Practice, 2013, 67, 1005-1014.	0.8	34
108	Saxagliptin Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease History or Cardiovascular Risk Factors: Results of a Pooled Analysis of Phase 3 Clinical Trials. Postgraduate Medicine, 2013, 125, 145-154.	0.9	9
109	In Vivo Efficacy of HD0471953: A Novel GPR119 Agonist for the Treatment of Type 2 Diabetes Mellitus. Journal of Diabetes Research, 2013, 2013, 1-6.	1.0	18
110	Nonalcoholic Fatty Liver: A Possible New Target for Type 2 Diabetes Prevention and Treatment. International Journal of Molecular Sciences, 2013, 14, 22933-22966.	1.8	88

#	Article	IF	Citations
111	Role of RACK1 in the differential proliferative effects of neuropeptide Y_{1â€“36} and peptide YY_{1â€“36} in SHR vs. WKY preglomerular vascular smooth muscle cells. American Journal of Physiology - Renal Physiology, 2013, 304, F770-F780.	1.3	14
112	Clinical utility and tolerability of linagliptin in diabetic patients. Drug, Healthcare and Patient Safety, 2013, 5, 67.	1.0	1
113	Lixisenatide as add-on therapy to basal insulin. Drug Design, Development and Therapy, 2013, 8, 25.	2.0	6
114	Enhancing Pancreatic Beta-Cell Regeneration In Vivo with Pioglitazone and Alogliptin. PLoS ONE, 2013, 8, e65777.	1.1	15
115	Bioassay-Guided Isolation of DPP-4 Inhibitory Fractions from Extracts of Submerged Cultured of Inonotus obliquus. Molecules, 2013, 18, 1150-1161.	1.7	29
116	Tolerability of Saxagliptin in Patients with Inadequately Controlled Type 2 Diabetes: Results from 6 Phase III Studies. Journal of Managed Care Pharmacy, 2014, 20, 120-129.	2.2	9
117	Effects of Dipeptidyl-Peptidase 4 Inhibitor about Vascular Inflammation in a Metabolic Syndrome Model. PLoS ONE, 2014, 9, e106563.	1.1	12
118	Pharmacophore Modeling and Molecular Docking Studies on Pinus roxburghii as a Target for Diabetes Mellitus. Advances in Bioinformatics, 2014, 2014, 1-8.	5.7	31
119	Interaction potential of Carmegliptin with P-glycoprotein (Pgp) transporter in healthy volunteers. Journal of Drug Assessment, 2014, 3, 28-37.	1.1	2
120	Novel DPP-4 inhibitors against diabetes. Future Medicinal Chemistry, 2014, 6, 793-808.	1.1	11
121	Sitagliptin Prevents Inflammation and Apoptotic Cell Death in the Kidney of Type 2 Diabetic Animals. Mediators of Inflammation, 2014, 2014, 1-15.	1.4	97
122	<scp>DPP</scp>4 Inhibitors increase differentially the expression of surfactant proteins in Fischer 344 rats. Acta Physiologica, 2014, 212, 248-261.	1.8	9
123	Bioequivalence of Saxagliptin/Metformin Extended-Release (XR) Fixed-Dose Combination Tablets and Single-Component Saxagliptin and Metformin XR Tablets in Healthy Adult Chinese Subjects. Clinical Drug Investigation, 2014, 34, 763-772.	1.1	3
124	Dipeptidyl peptidase-4 inhibitor reduces infarct size and preserves cardiac function via mitochondrial protection in ischaemiaâ€“reperfusion rat heart. Diabetes and Vascular Disease Research, 2014, 11, 75-83.	0.9	62
125	Effect of linagliptin, alone and in combination with voglibose or exendin-4, on glucose control in male ZDF rats. European Journal of Pharmacology, 2014, 729, 59-66.	1.7	11
126	Molecular dynamic simulations reveal the mechanism of binding between xanthine inhibitors and DPP-4. Journal of Molecular Modeling, 2014, 20, 2075.	0.8	5
127	Discovery of C-(1-aryl-cyclohexyl)-methylamines as selective, orally available inhibitors of dipeptidyl peptidase IV. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 731-736.	1.0	14
128	Saxagliptin efficacy and safety in patients with type 2 diabetes receiving concomitant statin therapy. Journal of Diabetes and Its Complications, 2014, 28, 887-893.	1.2	2

#	Article	IF	Citations
129	A grape seed extract increases active glucagon-like peptide-1 levels after an oral glucose load in rats. Food and Function, 2014, 5, 2357.	2.1	69
130	The Glucose-Dependent Insulinotropic Polypeptide Receptor: A Novel Target for Neuroendocrine Tumor Imagingâ€"First Preclinical Studies. Journal of Nuclear Medicine, 2014, 55, 976-982.	2.8	33
131	Analgesic and anti-inflammatory effectiveness of sitagliptin and vildagliptin in mice. Regulatory Peptides, 2014, 194-195, 23-29.	1.9	15
132	Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with TypeÂ2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24â€week randomized, doubleâ€blind study. Diabetic Medicine, 2014, 31, 1505-1514.	1.2	38
133	Population pharmacokinetic analysis of dutogliptin, a selective dipeptidyl peptidaseâ€4 inhibitor. Clinical Pharmacology in Drug Development, 2014, 3, 297-304.	0.8	0
134	GLP-1R activation for the treatment of stroke: Updating and future perspectives. Reviews in Endocrine and Metabolic Disorders, 2014, 15, 233-242.	2.6	21
135	The consumer welfare implications of governmental policies and firm strategy in markets for medicines. Journal of Health Economics, 2015, 44, 255-273.	1.3	27
136	Serum Levels of Soluble CD26/Dipeptidyl Peptidase-IV in Type 2 Diabetes Mellitus and Its Association with Metabolic Syndrome and Therapy with Antidiabetic Agents in Malaysian Subjects. PLoS ONE, 2015, 10, e0140618.	1.1	19
137	Effect of Glucagon-like Peptide-1 on the Differentiation of Adipose-derived Stem Cells into Osteoblasts and Adipocytes. Journal of Menopausal Medicine, 2015, 21, 93.	0.3	32
138	Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies. Drug Discovery Today, 2015, 20, 1061-1073.	3.2	400
139	Gemigliptin improves renal function and attenuates podocyte injury in mice with diabetic nephropathy. European Journal of Pharmacology, 2015, 761, 116-124.	1.7	40
140	Dipeptidyl peptidase-4 inhibitors: their role in the management of type 2 diabetes. Journal of Endocrinology Metabolism and Diabetes of South Africa, 2015, 20, 64-66.	0.4	2
141	NPY_{1â€"36}and PYY_{1â€"36}activate cardiac fibroblasts: an effect enhanced by genetic hypertension and inhibition of dipeptidyl peptidase 4. American Journal of Physiology - Heart and Circulatory Physiology, 2015, 309, H1528-H1542.	1.5	34
142	Linagliptin/metformin HCl (fixed combination therapy) for the treatment of Type 2 diabetes mellitus. Expert Review of Endocrinology and Metabolism, 2015, 10, 353-363.	1.2	0
143	Gemigliptin, a dipeptidyl peptidase-4 inhibitor, inhibits retinal pericyte injury in db/db mice and retinal neovascularization in mice with ischemic retinopathy. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 2618-2629.	1.8	17
144	Control de factores de riesgo cardiovascular en pacientes diabÃ©ticos revascularizados: un subanÃ¡lisis del estudio ICP-Bypass. Revista Espanola De Cardiologia, 2015, 68, 115-120.	0.6	9
145	Control of Cardiovascular Risk Factors in Revascularized Patients With Diabetes: A Subanalysis of the ICP-Bypass Study. Revista Espanola De Cardiologia (English Ed), 2015, 68, 115-120.	0.4	2
146	How our bodies fight amyloidosis: Effects of physiological factors on pathogenic aggregation of amyloidogenic proteins. Archives of Biochemistry and Biophysics, 2015, 568, 46-55.	1.4	31

#	Article	IF	Citations
147	Derivatization of diamondoids for functional applications. Journal of Materials Chemistry C, 2015, 3, 6947-6961.	2.7	39
148	A sensitive and selective liquid chromatography mass spectrometry method for simultaneous estimation of anti-diabetic drugs inhibiting DPP-4 enzyme in human plasma: overcoming challenges associated with low recovery and sensitivity. Analytical Methods, 2015, 7, 6198-6206.	1.3	16
149	Pharmaceuticals that contain polycyclic hydrocarbon scaffolds. Chemical Society Reviews, 2015, 44, 7737-7763.	18.7	175
150	Linagliptin improves glycemic control after 1 year as add-on therapy to basal insulin in Asian patients with type 2 diabetes mellitus. Current Medical Research and Opinion, 2015, 31, 503-512.	0.9	9
151	Development of multiplex mass spectrometric immunoassay for detection and quantification of apolipoproteins C-I, C-II, C-III and their proteoforms. Methods, 2015, 81, 86-92.	1.9	42
152	Structureâ€“activity-relationship of amide and sulfonamide analogs of omarigliptin. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 5767-5771.	1.0	16
153	Effect of Dipeptidyl Peptidase 4 Inhibition on Arterial Blood Pressure Is Context Dependent. Hypertension, 2015, 65, 238-249.	1.3	36
155	Pharmacological Modulators of Endoplasmic Reticulum Stress in Metabolic Diseases. International Journal of Molecular Sciences, 2016, 17, 192.	1.8	36
156	Computational screening of dipeptidyl peptidase IV inhibitors from micoroalgal metabolites by pharmacophore modeling and molecular docking. Phycological Research, 2016, 64, 291-299.	0.8	7
157	Efficacy and risk profile of anti-diabetic therapies: Conventional vs traditional drugsâ€”A mechanistic revisit to understand their mode of action. Pharmacological Research, 2016, 113, 636-674.	3.1	53
158	Cross-talk between the dipeptidyl peptidase-4 and stromal cell-derived factor-1 in stem cell homing and myocardial repair: Potential impact of dipeptidyl peptidase-4 inhibitors. , 2016, 167, 100-107.		47
159	Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system. Clinical and Experimental Immunology, 2016, 185, 1-21.	1.1	332
160	Effects of saxagliptin add-on therapy to insulin on blood glycemic fluctuations in patients with type 2 diabetes. Medicine (United States), 2016, 95, e5229.	0.4	13
161	Clinical and genetic predictors of dipeptidyl peptidase-4 inhibitor treatment response in Type 2 diabetes mellitus. Pharmacogenomics, 2016, 17, 867-881.	0.6	21
162	Linagliptin inhibits lipopolysaccharide-stimulated interleukin-6 production, intranuclear p65 expression, and p38 mitogen-activated protein kinase phosphorylation in human umbilical vein endothelial cells. Renal Replacement Therapy, 2016, 2, .	0.3	8
163	The protective effect of vildagliptin in chronic experimental cyclosporine A-induced hepatotoxicity. Canadian Journal of Physiology and Pharmacology, 2016, 94, 251-256.	0.7	12
164	Characteristics and Outcomes of Middle East Respiratory Syndrome Coronavirus Patients Admitted to an Intensive Care Unit in Jeddah, Saudi Arabia. Journal of Intensive Care Medicine, 2016, 31, 344-348.	1.3	59
165	Recent Advances in Effectâ€directed Enzyme Assays based on Thinâ€layer Chromatography. Phytochemical Analysis, 2017, 28, 74-86.	1.2	33

#	Article	IF	Citations
166	Apigenin attenuates hippocampal oxidative events, inflammation and pathological alterations in rats fed high fat, fructose diet. Biomedicine and Pharmacotherapy, 2017, 89, 323-331.	2.5	30
167	ZY15557, a novel, long acting inhibitor of dipeptidyl peptidaseâ€4, for the treatment of Type 2 diabetes mellitus. British Journal of Pharmacology, 2017, 174, 2346-2357.	2.7	6
168	Synthetic and phytocompounds based dipeptidyl peptidase-IV (DPP-IV) inhibitors for therapeutics of diabetes. Journal of Asian Natural Products Research, 2017, 19, 1036-1045.	0.7	19
169	Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials. Scientific Reports, 2017, 7, 44865.	1.6	28
170	Effect of Long-term Incretin-Based Therapies on Ischemic Heart Diseases in Patients with Type 2 Diabetes Mellitus: A Network Meta-analysis. Scientific Reports, 2017, 7, 15795.	1.6	15
171	The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3). Cardiovascular Diabetology, 2017, 16, 125.	2.7	24
172	Spontaneous intracranial hemorrhage in a patient with Middle East respiratory syndrome corona virus. Journal of King Abdulaziz University, Islamic Economics, 2017, 38, 196-200.	0.5	36
173	Sitagliptin, An Anti-diabetic Drug, Suppresses Estrogen Deficiency-Induced Osteoporosis In Vivo and Inhibits RANKL-Induced Osteoclast Formation and Bone Resorption In Vitro. Frontiers in Pharmacology, 2017, 8, 407.	1.6	36
174	INHIBITORY POTENCY OF WITHANIA SOMNIFERA EXTRACTS AGAINST DPP-4: AN IN VITRO EVALUATION. Tropical Journal of Obstetrics and Gynaecology, 2017, 15, 11.	0.3	1
175	IN VITRO ANTIDIABETIC EFFECTS OF FERULA ASSA-FOETIDA EXTRACTS THROUGH DIPEPTIDYL PEPTIDASE IV AND Î±-GLUCOSIDASE INHIBITORY ACTIVITY. Asian Journal of Pharmaceutical and Clinical Research, 2017, 10, 357.	0.3	11
176	Microvesicles as Emerging Biomarkers and Therapeutic Targets in Cardiometabolic Diseases. Genomics, Proteomics and Bioinformatics, 2018, 16, 50-62.	3.0	98
177	Simultaneous quantitative analysis of retagliptin and its main active metabolite in human multiple matrices by liquid chromatography tandem mass spectrometry. Analytical Methods, 2018, 10, 2108-2114.	1.3	2
178	Investigation of medicinal plants from Madagascar against DPP-IV linked to type 2 diabetes. South African Journal of Botany, 2018, 115, 113-119.	1.2	16
179	Crystal structures of a bacterial dipeptidyl peptidase IV reveal a novel substrate recognition mechanism distinct from that of mammalian orthologues. Scientific Reports, 2018, 8, 2714.	1.6	19
180	Flavonoid-rich extract of Chromolaena odorata modulate circulating GLP-1 in Wistar rats: computational evaluation of TGR5 involvement. 3 Biotech, 2018, 8, 124.	1.1	28
181	Glutamine-Elicited Secretion of Glucagon-Like Peptide 1 Is Governed by an Activated Glutamate Dehydrogenase. Diabetes, 2018, 67, 372-384.	0.3	20
182	Metabolic Syndrome and Nutritional Interventions. , 2018, , 257-276.		0
183	Incorporating salal berry (Gaultheria shallon) and blackcurrant (Ribes nigrum) pomace in yogurt for the development of a beverage with antidiabetic properties. Heliyon, 2018, 4, e00875.	1.4	25

#	Article	IF	Citations
184	Protective effects of gemigliptin against type II collagen degradation in human chondrocytes. Biomedicine and Pharmacotherapy, 2018, 104, 590-594.	2.5	11
185	Emergence of promising novel DPPâ€4 inhibitory heterocycles as antiâ€diabetic agents: A review. Archiv Der Pharmazie, 2018, 351, e1800127.	2.1	3
186	Nutritional, Functional and Bioactive Protein Hydrolysates. , 2019, , 456-464.		12
187	Identification of a Novel Scaffold for Inhibition of Dipeptidyl Peptidase-4. Journal of Computational Biology, 2019, 26, 1470-1486.	0.8	2
188	Cardiovascular risk of sitagliptin in treating patients with type 2 diabetes mellitus. Bioscience Reports, 2019, 39, .	1.1	4
189	Natural phenolic compounds potentiate hypoglycemia via inhibition of Dipeptidyl peptidase IV. Scientific Reports, 2019, 9, 15585.	1.6	32
190	Role of plant-derived alkaloids against diabetes and diabetes-related complications: a mechanism-based approach. Phytochemistry Reviews, 2019, 18, 1277-1298.	3.1	32
191	DIABETES MELLITUS TREATMENT: A RAPID REVIEW ON INNOVATIVE THERAPIES. Asian Journal of Pharmaceutical and Clinical Research, 2019, 12, 46.	0.3	2
192	Treatment Patterns in Patients With Newly Diagnosed Type 2 Diabetes in China: A Retrospective, Longitudinal Database Study. Clinical Therapeutics, 2019, 41, 1440-1452.	1.1	16
193	In Silico Analysis of Bioactive Peptides in Invasive Sea Grass Halophila stipulacea. Cells, 2019, 8, 557.	1.8	12
194	UHPLC Method Development for Determining Sitagliptin and Dapagliflozin in Lipid-Based Self-Nanoemulsifying Systems as Combined Dose in Commercial Products and its Application to Pharmacokinetic Study of Dapagliflozin in Rats. Pharmaceutical Chemistry Journal, 2019, 53, 79-87.	0.3	12
195	Network pharmacology-based analysis on bioactive anti-diabetic compounds in Potentilla discolor bunge. Journal of Ethnopharmacology, 2019, 241, 111905.	2.0	40
196	Menaquinone-4 Amplified Glucose-Stimulated Insulin Secretion in Isolated Mouse Pancreatic Islets and INS-1 Rat Insulinoma Cells. International Journal of Molecular Sciences, 2019, 20, 1995.	1.8	12
197	The scope of phytotherapy in southern African antidiabetic healthcare. Transactions of the Royal Society of South Africa, 2019, 74, 1-18.	0.8	9
198	Polyalthia Clerodane Diterpene Potentiates Hypoglycemia via Inhibition of Dipeptidyl Peptidase 4. International Journal of Molecular Sciences, 2019, 20, 530.	1.8	15
199	Covalent Inhibition in Drug Discovery. ChemMedChem, 2019, 14, 889-906.	1.6	168
200	Pharmacological Interventions to Attenuate Alzheimerâ€™s Disease Progression: The Story So Far. Current Alzheimer Research, 2019, 16, 261-277.	0.7	26
201	ACE inhibitory peptides in standard and fermented deer velvet: an in silico and in vitro investigation. BMC Complementary and Alternative Medicine, 2019, 19, 350.	3.7	8

#	Article	IF	Citations
202	Differential Effects of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors on Insulin Resistance and Î²-Cell Function in Type 2 Diabetes Mellitus: A Propensity Score-Matched Analysis. Diabetes Therapy, 2019, 10, 149-158.	1.2	9
203	Biological function of dipeptidyl peptidase-4 on type 2 diabetes patients and diabetic mice. Current Research in Translational Medicine, 2019, 67, 89-92.	1.2	5
204	Plant-Derived Bioactive Peptides: A Treatment to Cure Diabetes. International Journal of Peptide Research and Therapeutics, 2020, 26, 955-968.	0.9	64
205	A dipyrrole derivative from Aloe vera inhibits an anti-diabetic drug target Dipeptidyl Peptidase (DPP)-IV inÂvitro. Preparative Biochemistry and Biotechnology, 2020, 50, 511-520.	1.0	18
206	Synthesis and discovery of triazolo-pyridazine-6-yl-substituted piperazines as effective anti-diabetic drugs; evaluated over dipeptidyl peptidase-4 inhibition mechanism and insulinotropic activities. European Journal of Medicinal Chemistry, 2020, 187, 111912.	2.6	16
207	In vivo challenges of anti-diabetic peptide therapeutics: Gastrointestinal stability, toxicity and allergenicity. Trends in Food Science and Technology, 2020, 105, 161-175.	7.8	28
208	Cardiovascular Active Peptides of Marine Origin with ACE Inhibitory Activities: Potential Role as Anti-Hypertensive Drugs and in Prevention of SARS-CoV-2 Infection. International Journal of Molecular Sciences, 2020, 21, 8364.	1.8	14
209	Pharmacokinetic/Pharmacodynamic Interaction Between Evogliptin and Pioglitazone in Healthy Male Subjects . Drug Design, Development and Therapy, 2020, Volume 14, 4493-4502.	2.0	2
210	Chromatin and transcriptome changes in human myoblasts show spatio-temporal correlations and demonstrate DPP4 inhibition in differentiated myotubes. Scientific Reports, 2020, 10, 14336.	1.6	3
211	iDPPIV-SCM: A Sequence-Based Predictor for Identifying and Analyzing Dipeptidyl Peptidase IV (DPP-IV) Inhibitory Peptides Using a Scoring Card Method. Journal of Proteome Research, 2020, 19, 4125-4136.	1.8	66
212	Coronavirus in human diseases: Mechanisms and advances in clinical treatment. MedComm, 2020, 1, 270-301.	3.1	22
213	Protein and gene markers of metabolic dysfunction and inflammation together associate with functional connectivity in reward and motor circuits in depression. Brain, Behavior, and Immunity, 2020, 88, 193-202.	2.0	21
214	The potential DPP-4 inhibitors from Xiao-Ke-An improve the glucolipid metabolism via the activation of AKT/GSK-3Î² pathway. European Journal of Pharmacology, 2020, 882, 173272.	1.7	7
215	DPP (Dipeptidyl Peptidase)-4 Inhibitor Attenuates Ang II (Angiotensin II)â€“Induced Cardiac Hypertrophy via GLP (Glucagon-Like Peptide)-1â€“Dependent Suppression of Nox (Nicotinamide Adenine Dinucleotide) Tj ETQq1 1 0.784314 rgBT	1.3	24
216	Teneligliptin inhibits ILâ€1Î²â€induced degradation of extracellular matrix in human chondrocytes. Journal of Cellular Biochemistry, 2020, 121, 4450-4457.	1.2	5
217	Extraction and characterization of phycocyanin from Spirulina platensis and evaluation of its anticancer, antidiabetic and antiinflammatory effect. International Journal of Biological Macromolecules, 2020, 153, 256-263.	3.6	93
218	Application of online liquid chromatography/quadrupole timeâ€ofâ€flight electrospray ionization tandem mass spectrometry for structural characterization of linagliptin degradation products and related impurities. Rapid Communications in Mass Spectrometry, 2020, 34, e8874.	0.7	6
219	Polymorphisms in dipeptidyl peptidase 4 reduce host cell entry of Middle East respiratory syndrome coronavirus. Emerging Microbes and Infections, 2020, 9, 155-168.	3.0	77

#	Article	IF	Citations
220	Network Pharmacology-Based Dissection of the Anti-diabetic Mechanism of Lobelia chinensis. Frontiers in Pharmacology, 2020, 11, 347.	1.6	29
221	Microencapsulation as a tool to counteract the typical low bioavailability of polyphenols in the management of diabetes. Food and Chemical Toxicology, 2020, 139, 111248.	1.8	54
222	Pharmacophore- based virtual screening, 3D- QSAR, molecular docking approach for identification of potential dipeptidyl peptidase IV inhibitors. Journal of Biomolecular Structure and Dynamics, 2021, 39, 2021-2043.	2.0	12
223	Computational identification of potential dipeptidyl peptidase (DPP)-IV inhibitors: Structure based virtual screening, molecular dynamics simulation and knowledge based SAR studies. Journal of Molecular Structure, 2021, 1224, 129006.	1.8	9
224	Nitrogenous Compounds from Plant Origin in Management of Diabetes Mellitus. , 2021, , 235-249.		0
225	Safety and effectiveness of linagliptin in Korean patients with type 2 diabetes: A postmarketing surveillance study. Diabetes, Obesity and Metabolism, 2021, 23, 1208-1212.	2.2	2
226	Common targets for a deadly duo of diabetes mellitus and colon cancer: Catching two fish with one worm. European Journal of Pharmacology, 2021, 893, 173805.	1.7	7
227	Functional foods with dipeptidyl peptidaseâ€4 inhibitory potential and management of type 2 diabetes: A review. Food Frontiers, 2021, 2, 153-162.	3.7	16
228	Dipeptidyl Peptidase (DPP)-IV Inhibitors with Antioxidant Potential Isolated from Natural Sources: A Novel Approach for the Management of Diabetes. Pharmaceuticals, 2021, 14, 586.	1.7	33
229	Docking-based virtual screening studies aiming at the covalent inhibition of SARS-CoV-2 MPro by targeting the cysteine 145. Computational Biology and Chemistry, 2021, 92, 107463.	1.1	10
230	Recent Medicinal Chemistry Approach for the Development of Dipeptidyl Peptidase IV Inhibitors. Current Medicinal Chemistry, 2021, 28, 3595-3621.	1.2	4
231	Spared Nerve Injury Causes Sexually Dimorphic Mechanical Allodynia and Differential Gene Expression in Spinal Cords and Dorsal Root Ganglia in Rats. Molecular Neurobiology, 2021, 58, 5396-5419.	1.9	27
232	Bone marrow adipose tissue: Role in bone remodeling and energy metabolism. Best Practice and Research in Clinical Endocrinology and Metabolism, 2021, 35, 101545.	2.2	18
233	Reversible covalent inhibitors suppress enterovirus 71 infection by targeting the 3C protease. Antiviral Research, 2021, 192, 105102.	1.9	10
234	IL-6 family cytokines as potential therapeutic strategies to treat metabolic diseases. Cytokine, 2021, 144, 155549.	1.4	6
235	The Impact of Deranged Glucose Metabolism and Diabetes in The Pathogenesis and Prognosis of The Novel Sars-Cov-2: A Systematic Review of Literature. Current Diabetes Reviews, 2021, 17, .	0.6	1
236	Incretin Hormones: Pathophysiological Risk Factors and Potential Targets for Type 2 Diabetes. Journal of Obesity and Metabolic Syndrome, 2021, 30, 233-247.	1.5	3
238	Phytonutrients and Antioxidant Properties of Rice By-products. , 2020, , 41-68.		3

#	Article	IF	Citations
239	Targeting Dipeptidyl Peptidase-4 (DPP-4) and Fibroblast Activation Protein (FAP) for Diabetes and Cancer Therapy. RSC Drug Discovery Series, 2011, , 118-144.	0.2	5
240	Synthesis and cytotoxicity of oxindoles dispiro derivatives with thiohydantoin and adamantane fragments. Phosphorus, Sulfur and Silicon and the Related Elements, 2020, 195, 544-555.	0.8	9
241	Periplasmic form of dipeptidyl aminopeptidase IV fromPseudoxanthomonas mexicanaWO24: purification, kinetic characterization, crystallization and X-ray crystallographic analysis. Acta Crystallographica Section F, Structural Biology Communications, 2017, 73, 601-606.	0.4	1
242	Dual Inhibition of DPP-4 and Cholinesterase Enzymes by the Phytoconstituents of the Ethanolic Extract of Prosopis cineraria Pods: Therapeutic Implications for the Treatment of Diabetes-associated Neurological Impairments. Current Alzheimer Research, 2020, 16, 1230-1244.	0.7	7
243	Identification of Phenolic Compounds from Nettle as New Candidate Inhibitors of Main Enzymes Responsible on Type-II Diabetes. Current Drug Discovery Technologies, 2020, 17, 197-202.	0.6	9
244	Dipeptidyl Peptidase Inhibitors: A New Step Towards Normoglycemia. The Open Endocrinology Journal, 2009, 3, 16-21.	0.1	2
245	Effect of Sitagliptin and Metformin on Prediabetes Progression to Type 2 Diabetes - A Randomized, Double-Blind, Double-Arm, Multicenter Clinical Trial: Protocol for the Sitagliptin and Metformin in PreDiabetes (SiMePreD) Study. JMIR Research Protocols, 2016, 5, e145.	0.5	12
247	Antidiabetic Activity and Phytochemical Screening of Extracts from Indonesian Plants by Inhibition of Alpha Amylase, Alpha Glucosidase and Dipeptidyl Peptidase IV. Pakistan Journal of Biological Sciences, 2015, 18, 279-284.	0.2	66
248	HD047703, a New Promising Anti-Diabetic Drug Candidate: In Vivo Preclinical Studies. Biomolecules and Therapeutics, 2014, 22, 400-405.	1.1	5
249	The potential role of vildagliptin in the management and prevention of type 2 diabetes mellitus. Indian Journal of Pharmacology, 2008, 40, 10.	0.4	9
250	Metabolic Syndrome: From Human Organ Disease to Fetal Programming. Journal of Metabolic Syndrome, 2014, 03, .	0.1	1
251	Czy leczenie inhibitorami DPP-4 ma wpÅ‚yw na subpopulacje limfocytÃ³w u chorych na cukrzycÄ™ typu 2?. Endokrynologia Polska, 2014, 65, 78-82.	0.3	3
252	Anti-diabetic Treatment in Obese Patients with Type 2 Diabetes Effects of Medication on Body Weight. US Endocrinology, 2006, 00, .	0.3	0
253	Ingibitor dipeptidilpeptidazy-IV - sitagliptin: novye vozmozhnosti terapii sakharnogo diabeta 2 tipa. Obesity and Metabolism, 2006, 3, 22-28.	0.4	0
255	Virtual Screening of Dipeptidyl Peptidase IV Inhibitors from Zinc Database. International Journal of Computer Applications, 2012, 56, 31-34.	0.2	5
256	Effects of the DPP-4 Inhibitor, Linagliptin, in Diet-Induced Obese Rats: A Comparison in Naive and Exenatide-Treated Animals. Clinical Laboratory, 2013, 59, .	0.2	5
257	The Efficacy and Safety of Saxagliptin in Haemodialysis Patients. Open Journal of Nephrology, 2013, 03, 83-88.	0.0	0
258	The Welfare Implications of Patent Protection, Pricing, and Licensing in the Indian Oral Anti-Diabetic Drug Market. SSRN Electronic Journal, 0, , .	0.4	0

#	Article	IF	Citations
259	Efficacy and safety of saxagliptin in type 2 diabetic patients undergoing hemodialysis. Nihon Toseki Igakkai Zasshi, 2014, 47, 731-736.	0.2	1
260	Characterization of Dipeptidyl Peptidase IV Enzyme Activity in Serum of the Komodo Dragon (Varanus) Tj ETQq1 1 0.784314 rgBT /Ov	0.1	2
261	DIABETES MELLITUS TREATMENT: A RAPID REVIEW ON INNOVATIVE THERAPIES. Asian Journal of Pharmaceutical and Clinical Research, 2019, 12, 46.	0.3	0
262	Difference of Acidic Adding Effect in Ethanol Extraction of White Mulberry Stem Bark (Morus alba) and DPP-4 Inhibiting Activity Screening for Identifying its Antidiabetic Potential. Pharmacognosy Journal, 2019, 11, 790-795.	0.3	1
263	Tombul hazelnut (Corylus avellana L.) peptides with DPP-IV inhibitory activity: In vitro and in silico studies. Food Chemistry: X, 2021, 12, 100151.	1.8	10
264	Pharmacological management of metabolic syndrome and its lipid complications. DARU, Journal of Pharmaceutical Sciences, 2010, 18, 146-54.	0.9	15
265	Management of type-2 diabetes mellitus in adults: focus on individualizing non-insulin therapies. P and T, 2012, 37, 687-96.	1.0	10
266	Naturally occurring mutations in G protein-coupled receptors associated with obesity and type 2 diabetes mellitus. , 2022, 234, 108044.		13
267	New quinoxaline compounds as DPP-4 inhibitors and hypoglycemics: design, synthesis, computational and bio-distribution studies. RSC Advances, 2021, 11, 36989-37010.	1.7	13
268	Synthesis, structural analysis, vibrational properties, and chiral separation of Xanthine-Quinazoline diastereomers. Journal of Molecular Structure, 2022, 1253, 132311.	1.8	0
269	Design, synthesis and in-silico & in vitro enzymatic inhibition assays of pyrazole-chalcone derivatives as dual inhibitors of Î±-amylase & DPP-4 enzyme. Chemical Papers, 2022, 76, 1707-1720.	1.0	4
270	Pyrrolidine Derivatives as Antiâ€diabetic Agents: Current Status and Future Prospects. ChemistrySelect, 2022, 7, .	0.7	10
271	Gastrointestinal Incretinsâ€"Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) beyond Pleiotropic Physiological Effects Are Involved in Pathophysiology of Atherosclerosis and Coronary Artery Diseaseâ€"State of the Art. Biology, 2022, 11, 288.	1.3	9
272	The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates Endothelial Inflammation and Microvascular Thrombosis in a Sepsis Mouse Model. International Journal of Molecular Sciences, 2022, 23, 3065.	1.8	8
273	Preclinical and clinical evaluation of nanodrugs for diabetes treatment. , 2022, , 225-246.		0
277	Polycystic ovarian syndrome-current pharmacotherapy and clinical implications. Taiwanese Journal of Obstetrics and Gynecology, 2022, 61, 40-50.	0.5	34
278	A Treatment to Cure Diabetes Using Plant-Based Drug Discovery. Evidence-based Complementary and Alternative Medicine, 2022, 2022, 1-12.	0.5	3
279	Sodium Glucose Cotransporter-2 Inhibitors as an Add-on Therapy to Metformin Plus Dipeptidyl Peptidase-4 Inhibitor in Patients with Type 2 Diabetes. Yonsei Medical Journal, 2022, 63, 539.	0.9	0

#	Article	IF	Citations
281	The Proteome of Extracellular Vesicles Produced by the Human Gut Bacteria Bacteroides thetaiotaomicron In Vivo Is Influenced by Environmental and Host-Derived Factors. Applied and Environmental Microbiology, 2022, 88, .	1.4	11
282	Exploitation of Olive (Olea europaea L.) Seed Proteins as Upgraded Source of Bioactive Peptides with Multifunctional Properties: Focus on Antioxidant and Dipeptidyl-Dipeptidaseâ€"IV Inhibitory Activities, and Glucagon-like Peptide 1 Improved Modulation. Antioxidants, 2022, 11, 1730.	2.2	5
283	Heterocyclic Compounds as Dipeptidyl Peptidase-IV Inhibitors with Special Emphasis on Oxadiazoles as Potent Anti-Diabetic Agents. Molecules, 2022, 27, 6001.	1.7	10
284	Polyphenol-Rich Leaf of Annona squamosa Stimulates Insulin Release from BRIN-BD11 Cells and Isolated Mouse Islets, Reduces (CH2O)n Digestion and Absorption, and Improves Glucose Tolerance and GLP-1 (7-36) Levels in High-Fat-Fed Rats. Metabolites, 2022, 12, 995.	1.3	2
285	A review on phytochemical and pharmacological facets of tropical ethnomedicinal plants as reformed DPP-IV inhibitors to regulate incretin activity. Frontiers in Endocrinology, 0, 13, .	1.5	12
286	Stem Cell Therapy in Combination with Naturopathy: Current Progressive Management of Diabetes and Associated Complications. Current Topics in Medicinal Chemistry, 2023, 23, 649-689.	1.0	6
287	Antioxidant, Anti-Diabetic, Anti-Obesity, and Antihypertensive Properties of Protein Hydrolysate and Peptide Fractions from Black Sesame Cake. Molecules, 2023, 28, 211.	1.7	9
288	Virtual Screening, Synthesis, and Biological Evaluation of Some Carbohydrazide Derivatives as Potential DPP-IV Inhibitors. Molecules, 2023, 28, 149.	1.7	3
289	Yogliptin monotherapy in type 2 diabetes: A 12â€week randomized, doubleâ€blind, placeboâ€controlled phase <scp>II</scp> study. Journal of Diabetes, 2022, 14, 822-830.	0.8	2
290	Beneficial Effects of Dipeptidyl Peptidase-4 Inhibitors on HeartÂFailureÂWith Preserved EjectionÂFraction and Diabetes. JACC Asia, 2023, 3, 93-104.	0.5	8
291	Unlocking the bioactivity of meat proteins: Comparison of meat and meat hydrolysate via simulated gastrointestinal digestion. Journal of Proteomics, 2023, 273, 104806.	1.2	4
292	Unveiling the prevalence and impact of diabetes on COVID-19. , 2023, , 287-301.		0
293	A review on the types of amino acid at ultimate, penultimate and antepenultimate position in some dipeptidyl-peptidase IV inhibitory peptides based on molecular docking analysis. , 2023, 2, 100244.		3
294	Scale-Up Synthesis of 1-Methyladamantane and Its Functionalization as a Key Point for Promising Antiviral Agents. Organic Process Research and Development, 2023, 27, 477-487.	1.3	1
295	Dipeptidyl Peptidase-4 Inhibitory Activity of Indonesian Anti-Diabetic Herbs: Carica papaya, Tithonia diversifolia, Urena lobata. Research Journal of Pharmacy and Technology, 2023, , 273-277.	0.2	1
296	Molecular Mechanisms in the Etiology of Polycystic Ovary Syndrome (PCOS): A Multifaceted Hypothesis Towards the Disease with Potential Therapeutics. Indian Journal of Clinical Biochemistry, 2024, 39, 18-36.	0.9	2
297	Covalent Modifier Discovery Using Hydrogen/Deuterium Exchangeâ€"Mass Spectrometry. Journal of Medicinal Chemistry, 2023, 66, 4827-4839.	2.9	0
305	Divergent Approaches Toward Drug Discovery and Development. , 2023, , 557-578.		0

#	Article	IF	Citations